WO2013043085A8 - Состав (rs)-2-(2-оксо-4-фенилпирролидин-1-ил)ацетамид, обладающий модуляторной активностью с соразмерным влиянием, фармацевтический состав субстанции (варианты) и его применение, композиция (варианты) - Google Patents
Состав (rs)-2-(2-оксо-4-фенилпирролидин-1-ил)ацетамид, обладающий модуляторной активностью с соразмерным влиянием, фармацевтический состав субстанции (варианты) и его применение, композиция (варианты) Download PDFInfo
- Publication number
- WO2013043085A8 WO2013043085A8 PCT/RU2012/000773 RU2012000773W WO2013043085A8 WO 2013043085 A8 WO2013043085 A8 WO 2013043085A8 RU 2012000773 W RU2012000773 W RU 2012000773W WO 2013043085 A8 WO2013043085 A8 WO 2013043085A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variants
- phenylpyrrolidin
- oxo
- modulatory activity
- composition
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/16—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using titration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/16—Separation or purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/18—Stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014531758A JP2014526551A (ja) | 2011-09-22 | 2012-09-20 | 相応の作用を伴う調節活性を有している(rs)−2−(2−オキソ−4−フェニルピロリジン−1−イル)アセトアミド化合物、医薬物質(変種)およびその適用、それらの組成物(変形) |
MX2014003483A MX2014003483A (es) | 2011-09-22 | 2012-09-20 | (rs) -2- (2-oxo-4-fenilpirrolidin-1-il)acetamida compuesto que tiene actividad moduladora con un efecto proporcionado, sustancia farmaceutica (variantes) y su aplicacion, y composicion (variantes) de la misma. |
CN201280057155.8A CN103987386A (zh) | 2011-09-22 | 2012-09-20 | 具有有相称效果的调节活性的(rs)-2-(2-氧代-4-苯基吡咯烷-1-基)乙酰胺化合物、药物物质(变体)及其应用、其组合物(变体) |
BR112014006910A BR112014006910A2 (pt) | 2011-09-22 | 2012-09-20 | composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica |
EA201490615A EA201490615A1 (ru) | 2011-09-22 | 2012-09-20 | Состав (rs)-2-(2-оксо-4-фенилпирролидин-1-ил)ацетамид, обладающий модуляторной активностью с соразмерным влиянием, фармацевтический состав субстанции (варианты) и его применение, композиция (варианты) |
MD20140042A MD20140042A2 (ru) | 2011-09-22 | 2012-09-20 | Соединение (RS)-2-(2-оксо-4-фенилпирролидин-1-ил)ацетамид обладающее модуляторной активностью с соразмерным влиянием, фармацевтический состав субстанции (варианты) и его применение, композиция (варианты) |
US14/346,445 US20140315972A1 (en) | 2011-09-22 | 2012-09-20 | RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants) and its application, composition (variants) thereof |
CA 2849711 CA2849711A1 (en) | 2011-09-22 | 2012-09-20 | (rs)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants) and its application, composition (variants) thereof |
UAA201403117A UA111981C2 (uk) | 2011-09-22 | 2012-09-20 | Сполука (rs)-2-(2-оксо-4-фенілпіролідин-1-іл)ацетамід, яка має модуляторну активність з пропорційним впливом, фармацевтичний склад субстанції (варіанти) та його застосування, композиція (варіанти) |
EP12834473.6A EP2762138A4 (en) | 2011-09-22 | 2012-09-20 | PHARMACEUTICAL ACTIVE SUBSTANCE (VARIANT) AND COMPOSITIONS BASED ON IT WITH MODULATING ACTIVITY WITH A CORRESPONDING EFFECT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011138840/15A RU2480214C1 (ru) | 2011-09-22 | 2011-09-22 | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
RU2011138840 | 2011-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013043085A1 WO2013043085A1 (ru) | 2013-03-28 |
WO2013043085A8 true WO2013043085A8 (ru) | 2013-10-31 |
Family
ID=47914659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2012/000773 WO2013043085A1 (ru) | 2011-09-22 | 2012-09-20 | Фармацевтическая субстанция (варианты) и полученные на ее основе композиции, обладающие модуляторной активностью с соразмерным влиянием |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140315972A1 (ru) |
EP (1) | EP2762138A4 (ru) |
JP (1) | JP2014526551A (ru) |
CN (1) | CN103987386A (ru) |
BR (1) | BR112014006910A2 (ru) |
CA (1) | CA2849711A1 (ru) |
EA (1) | EA201490615A1 (ru) |
MD (1) | MD20140042A2 (ru) |
MX (1) | MX2014003483A (ru) |
RU (1) | RU2480214C1 (ru) |
UA (1) | UA111981C2 (ru) |
WO (1) | WO2013043085A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2524651C1 (ru) * | 2013-06-20 | 2014-07-27 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция в форме раствора для инъекций и способ ее получения |
LV15003B (lv) * | 2013-10-22 | 2015-08-20 | Latvijas Organiskās Sintēzes Institūts | Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei |
RU2539375C1 (ru) * | 2013-11-07 | 2015-01-20 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция в форме таблетки и способ ее получения |
EP2891491A1 (en) * | 2014-01-03 | 2015-07-08 | Merz Pharma GmbH & Co. KGaA | Use of (r)-phenylpiracetam for the treatment of sleep disorders |
EP3127539A1 (en) * | 2015-08-03 | 2017-02-08 | Latvian Institute Of Organic Synthesis | Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures |
RU2748419C2 (ru) * | 2017-02-20 | 2021-05-25 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Производные 4-фенилпирролидона, обладающие противосудорожной и ноотропной активностью, как средства лечения эпилепсии и пароксизмальных состояний |
RU2696277C2 (ru) * | 2017-08-15 | 2019-08-01 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новый состав N-карбамоилметил-4-фенил-2-пирролидона |
LV15614A (lv) * | 2020-07-30 | 2022-02-20 | Latvijas Organiskās Sintēzes Institūts | 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU797219A1 (ru) * | 1979-05-08 | 1995-07-25 | Ленинградский государственный педагогический институт им.А.И.Герцена | N-карбамоилметил-4-фенил-2-пирролидон, обладающий гипотензивной активностью |
SU1265192A1 (ru) * | 1984-06-27 | 1986-10-23 | 2-Ой Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова | Способ получени амидов 4-фенил-пирролидон-2-уксусной-1 кислоты |
EP0363489A4 (en) * | 1988-04-18 | 1991-09-11 | Mo Med Inst Pirogova | Method for obtaining 4-phenyl-2-pyrrolidone-acetic-1 acid amide |
RU2050851C1 (ru) * | 1990-08-28 | 1995-12-27 | Институт медико-биологических проблем | Вещество, проявляющее ноотропную активность |
EA002380B1 (ru) * | 1999-07-21 | 2002-04-25 | Российский Государственный Педагогический Университет Им. А.И.Герцена | Антиишемическое средство |
US6423739B1 (en) * | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
RU2183117C1 (ru) * | 2000-11-03 | 2002-06-10 | Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" | Средство для нормализации артериального давления и способ лечения гипертонической болезни |
RU2192858C1 (ru) * | 2001-05-16 | 2002-11-20 | Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" | Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью |
RU2232578C1 (ru) * | 2003-04-10 | 2004-07-20 | Ахапкина Валентина Ивановна | Вещество, обладающее антидепрессивной активностью |
RU2240783C1 (ru) * | 2003-07-17 | 2004-11-27 | Открытое акционерное общество "Щелковский витаминный завод" | Фармацевтическая композиция, обладающая ноотропной активностью, и способ ее получения |
RU2289404C1 (ru) * | 2005-04-06 | 2006-12-20 | ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" | Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах |
LV13630B (en) | 2006-03-16 | 2007-12-20 | Olainfarm As | Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone |
WO2007111582A1 (en) * | 2006-03-24 | 2007-10-04 | Panasonic Automotive Systems Company Of America Division Of Panasonic Corporation Of North America | Audio system with parental maximum volume control |
RU2329804C2 (ru) * | 2006-03-28 | 2008-07-27 | Валентина Ивановна Ахапкина | Вещество, обладающее нейротропной - нейромодуляторной активностью |
WO2008012268A1 (en) * | 2006-07-25 | 2008-01-31 | Zach System S.P.A. | Process for the preparation of levetiracetam |
RU2327458C1 (ru) * | 2007-02-19 | 2008-06-27 | Открытое акционерное общество "Щелковский витаминный завод" | Новая препаративная форма вещества, обладающего ноотропной и нейромодуляторной активностью, и способ ее получения |
RU2423969C2 (ru) | 2007-10-12 | 2011-07-20 | Старрайд Фармасьютикал Лимитед | Способ микронизации n-карбамоил-метил-4-фенил-2-пирролидона и лекарственный препарат, содержащий вододиспергируемую органическую лекарственную субстанцию в виде микронизированного порошка n-карбамоил-метил-4-фенил-2-пирролидона |
RU2391976C2 (ru) * | 2007-10-18 | 2010-06-20 | Открытое Акционерное Общество "Валента Фармацевтика" | Фармацевтический состав в виде микроинкапсулированных поликомпонентных частиц из n-карбамоил-метил-4-фенил-2-пирролидона и вспомогательного нейтрального органического низкомолекулярного компонента и способ его микрокапсулирования |
US20090176740A1 (en) * | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
EP2278999A4 (en) | 2008-04-21 | 2015-04-22 | Otonomy Inc | EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES |
JP2010024156A (ja) * | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
MX2011001384A (es) * | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
RU2392915C1 (ru) * | 2009-04-14 | 2010-06-27 | Федеральное государственное учреждение "Новокузнецкий научно-практический центр медико-социальной экспертизы и реабилитации инвалидов Федерального агентства по здравоохранению и социальному развитию" (ФГУ ННПЦ МСЭ и РИ Росздрава) | Способ формирования двигательных функций у инвалидов с позвоночно-спинно-мозговой травмой |
RU2414898C1 (ru) * | 2009-09-18 | 2011-03-27 | Открытое Акционерное Общество "Валента Фармацевтика" | Фармацевтическая композиция в форме раствора для инъекций, обладающая ноотропной активностью, и способ ее получения |
ES2664727T3 (es) * | 2009-10-22 | 2018-04-23 | University College Dublin National University Of Ireland, Dublin | Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP |
RU2418588C1 (ru) * | 2009-12-28 | 2011-05-20 | Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Психического Здоровья Сибирского Отделения Рамн | Способ лечения эндометриоза у женщин с тревожно-депрессивными расстройствами |
-
2011
- 2011-09-22 RU RU2011138840/15A patent/RU2480214C1/ru not_active IP Right Cessation
-
2012
- 2012-09-20 JP JP2014531758A patent/JP2014526551A/ja active Pending
- 2012-09-20 EP EP12834473.6A patent/EP2762138A4/en not_active Withdrawn
- 2012-09-20 WO PCT/RU2012/000773 patent/WO2013043085A1/ru active Application Filing
- 2012-09-20 BR BR112014006910A patent/BR112014006910A2/pt not_active Application Discontinuation
- 2012-09-20 MX MX2014003483A patent/MX2014003483A/es unknown
- 2012-09-20 CN CN201280057155.8A patent/CN103987386A/zh active Pending
- 2012-09-20 UA UAA201403117A patent/UA111981C2/uk unknown
- 2012-09-20 MD MD20140042A patent/MD20140042A2/ru not_active Application Discontinuation
- 2012-09-20 EA EA201490615A patent/EA201490615A1/ru unknown
- 2012-09-20 US US14/346,445 patent/US20140315972A1/en not_active Abandoned
- 2012-09-20 CA CA 2849711 patent/CA2849711A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA201490615A1 (ru) | 2014-06-30 |
EP2762138A4 (en) | 2015-12-02 |
RU2480214C1 (ru) | 2013-04-27 |
MD20140042A2 (ru) | 2014-09-30 |
MX2014003483A (es) | 2014-11-10 |
JP2014526551A (ja) | 2014-10-06 |
EP2762138A1 (en) | 2014-08-06 |
CN103987386A (zh) | 2014-08-13 |
US20140315972A1 (en) | 2014-10-23 |
RU2011138840A (ru) | 2013-03-27 |
UA111981C2 (uk) | 2016-07-11 |
BR112014006910A2 (pt) | 2017-04-11 |
CA2849711A1 (en) | 2013-03-28 |
WO2013043085A1 (ru) | 2013-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013043085A8 (ru) | Состав (rs)-2-(2-оксо-4-фенилпирролидин-1-ил)ацетамид, обладающий модуляторной активностью с соразмерным влиянием, фармацевтический состав субстанции (варианты) и его применение, композиция (варианты) | |
IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
WO2014062733A3 (en) | Substituted benzene compounds | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
EA201590457A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
WO2016127179A3 (en) | Immunomodulatory agents | |
WO2012104263A3 (en) | 1,4 oxazines as bace1 and/or bace2 inhibitors | |
PH12015502535A1 (en) | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | |
EA201992707A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
EP3178482A4 (en) | Applications of phillyrin/phillygenin composition in preparing drugs or health care products for relieving and/or treating viral diseases | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
PH12015502365A1 (en) | Bace1 inhibitors | |
PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
MY191980A (en) | Formulations containing an extract of echinacea and linoleic acid derivatives | |
NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
CY1118198T1 (el) | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων | |
BR112013022651A2 (pt) | material transportador carregado com ácido em pó | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12834473 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2849711 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/003483 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2014531758 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012834473 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201403117 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490615 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13443 Country of ref document: GE |
|
ENP | Entry into the national phase |
Ref document number: 20140042 Country of ref document: MD Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A 2014 0042 Country of ref document: MD |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14346445 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014006910 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014006910 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140321 |